If you have knee arthritis, taking certain diabetes weight-loss drugs like semaglutide or liraglutide can help you lose around 7.5 kilograms on average, mostly because they help control your hunger and energy use, which might also take some pressure off your joints.
See the scientific wording
GLP-1 receptor agonists, including semaglutide and liraglutide, result in clinically significant reductions in body weight and BMI among adults with knee osteoarthritis, with an average weight loss of 7.56 kg (95% CI: −14.71 to −0.41) and a BMI reduction of 4.51 kg/m² (95% CI: −9.02 to −0.01), primarily due to their effects on appetite regulation and energy balance, which may indirectly improve joint loading in osteoarthritis.
Strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis
The study looks at the same weight-loss drugs mentioned in the claim and suggests they can help with knee osteoarthritis by reducing weight, which makes sense because carrying less weight is easier on the joints.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
If you have knee arthritis, taking certain diabetes weight-loss drugs like semaglutide or liraglutide can help you lose around 7.5 kilograms on average, mostly because they help control your hunger and energy use, which might also take some pressure off your joints.
Evidence from Studies
Supporting (1)
Community contributions welcome
Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Knee Osteoarthritis: A Systematic Review and Meta-Analysis
The study looks at the same weight-loss drugs mentioned in the claim and suggests they can help with knee osteoarthritis by reducing weight, which makes sense because carrying less weight is easier on the joints.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists on Weight Loss and BMI in Adults with Knee Osteoarthritis
Systematic review of randomized controlled trials assessing GLP-1 agonists vs. placebo or standard care in adults with knee osteoarthritis, measuring changes in body weight and BMI over ≥12 weeks, with predefined inclusion criteria and risk of bias assessment.
Double-Blind Randomized Controlled Trial of Semaglutide vs. Placebo for Weight Reduction in Adults with Knee Osteoarthritis
Double-blind, placebo-controlled RCT with adults diagnosed with knee osteoarthritis, randomized to semaglutide (e.g., 2.4 mg weekly) or placebo for 68 weeks, measuring primary outcomes of body weight and BMI change, with secondary joint loading assessments via gait analysis.
Prospective Cohort Study of Liraglutide Use and Long-Term Weight Trajectory in Patients with Knee Osteoarthritis
Longitudinal cohort of adults with knee osteoarthritis initiating liraglutide vs. matched controls not using GLP-1 agonists, followed for ≥1 year to assess weight, BMI, and mobility outcomes using standardized measures.
Case-Control Study of Significant Weight Loss in Knee Osteoarthritis Patients: GLP-1 Agonist Use as a Predictor
Matched case-control study comparing patients with knee osteoarthritis who lost >5% body weight (cases) vs. those who did not (controls), assessing prior exposure to GLP-1 agonists while adjusting for diabetes status, age, and baseline BMI.
National Survey-Based Cross-Sectional Study of GLP-1 Agonist Use and BMI in Adults with Knee Osteoarthritis
Analysis of nationally representative health survey data including adults with knee osteoarthritis, comparing mean BMI and weight between current users and non-users of GLP-1 receptor agonists, adjusted for key covariates.